Company Dossier · Health Care
Cigna
- S&P 500
- Russell 1000
What Cigna is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $282 billion, up 7.8% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to December 31, 2019: $8.44 billion, up 160% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to December 31, 2019: $1.05 billion, up 98% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $3.62 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $4.46 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 30, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 2 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 26, 2026): 0 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $6.3 million on the open market.SEC Form 4
- 1,702 institutional managers reported a position at June 30, 2026 (+41 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 126 (151 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Cigna is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Expanding ↔ Retrenching
Withheld: 50% of the evidence is readable at this date (needs 60%).
- Capital spending—
- Debt raised—
- Buybacks vs capex—
- Hiring filings71st pct
- Deals and private raises49th pct
- Patent publications77th pct
Confident ↔ Hedging
Confident
- Call sentiment76th pct
- Call confidence54th pct
- Guidance changes80th pct
- Risk factors added73rd pct
- Insider open-market trades37th pct
- + Guidance changes
- + Call sentiment
- + Risk factors added
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver5th pct
- Stress filings48th pct
Credit
How these are built →Cigna's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$31.9B
- Due within a year $2.8B
- Longer term $29.1B
- Default point $17.3B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
| Priced | Amount | Coupon | Matures | Spread | Yield |
|---|---|---|---|---|---|
| Sep 2, 2025 | $750M | 6.000% | 2056 (30y) | +110bp | 6.070% |
| Sep 2, 2025 | $1B | 4.500% | 2030 (5y) | +80bp | 4.546% |
| Sep 2, 2025 | $1.25B | 4.875% | 2032 (7y) | +90bp | 4.876% |
| Sep 2, 2025 | $1.5B | 5.250% | 2036 (10y) | +100bp | 5.275% |
| Feb 5, 2024 | $1.5B | 5.600% | 2054 (30y) | +125bp | 5.610% |
| Feb 5, 2024 | $750M | 5.125% | 2031 (7y) | +100bp | 5.151% |
| Feb 5, 2024 | $1.25B | 5.250% | 2034 (10y) | +110bp | 5.256% |
| Feb 5, 2024 | $1B | 5.000% | 2029 (5y) | +90bp | 5.026% |
From the pricing term sheets Cigna filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Cigna: guidance raised minus lowered
Guidance Ledger statements by quarter
Cigna: earnings call sentiment
Palanor Discourse score per call, −1 to +1
Hiring and ownership
In the news
Headlines that name Cigna, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralCigna: Deeply Undervalued With Double-Digit EPS Growth Ahead (NYSE:CI)
seekingalpha.com · via Marketaux · Oct 1, 2026
- NeutralCigna sets aside $3B to boost performance (CI:NYSE)
seekingalpha.com · via Marketaux · Sep 30, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES))third_quarter 2026 · $2.6 million
- Oct 20, 2026LobbyingLobbying report (CAPITOL HILL CONSULTING GROUP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (RED+BLUE STRATEGIES)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (ATLAS CROSSING LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (BANNER PUBLIC AFFAIRS, LLC)third_quarter 2026 · $0.0 million
- Oct 20, 2026LobbyingLobbying report (POLARIS GOVERNMENT RELATIONS, LLC)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (TIBER CREEK GROUP)third_quarter 2026 · $0.1 million
- Oct 19, 2026LobbyingLobbying report (WILMER CUTLER PICKERING HALE AND DORR LLP)third_quarter 2026
- Oct 9, 20268-KDirector or officer changeItem 5.02
- Aug 25, 2026Patent
- Apr 27, 20268-KShareholder vote resultsItem 5.07
- Mar 3, 20268-KDirector or officer changeItem 5.02
- Feb 26, 202610-KAnnual report (10-K)0 risk factors added, 1 removed
- Dec 9, 2025Patent
- Oct 20, 20258-KDirector or officer changeItem 5.02
- Sep 4, 20258-KMaterial agreement signedItem 1.01
- Jul 28, 20258-KDirector or officer changeItem 5.02
- Jul 8, 2025Patent
- Jul 1, 2025Patent
- Jun 10, 2025Patent
- Jun 2, 20258-KDirector or officer changeItem 5.02
- Apr 28, 20258-KMaterial agreement terminatedItem 1.02
- Apr 28, 20258-KDirector or officer changeItem 5.02
- Apr 28, 20258-KShareholder vote resultsItem 5.07
- Apr 28, 20258-KMaterial agreement signedItem 1.01
- Apr 18, 20258-KDirector or officer changeItem 5.02
- Mar 13, 20258-KDirector or officer changeItem 5.02
- Feb 27, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Feb 29, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| CVS Health CVS | $415B | $11.8B | Jun 30, 2026 |
| Labcorp LH | $14.3B | $1.2B | Jun 30, 2026 |
| DaVita DVA | $14.0B | $1.6B | Jun 30, 2026 |
| Quest Diagnostics DGX | $11.6B | $1.4B | Jun 30, 2026 |
| Chemed Corporation CHE | $2.6B | $0.3B | Jun 30, 2026 |
| Cardinal Health CAH | $245B | $5.5B | Dec 31, 2025 |
| Cencora COR | $333B | $4.1B | Jun 30, 2026 |
| Elevance Health ELV | $201B | $6.3B | Jun 30, 2026 |